Pharmaceutical

Ji Xing acquires Biogen’s BIIB131 for acute ischemic stroke

Ji Xing Pharmaceuticals acquired Biogen’s BIIB131 for advancing worldwide clinical developments in treating acute ischemic stroke (AIS).

Jan 13, 2024 - 18:00
Ji Xing acquires Biogen’s BIIB131 for acute ischemic stroke
Ji Xing Pharmaceuticals acquired Biogen’s BIIB131 for advancing worldwide clinical developments in treating acute ischemic stroke (AIS).
Read the original article

Tags:

Previous Article

Dermavant maps out atopic dermatitis filing after positive Phase III data 

Next Article

ClinChoice enhances global reach with CSI Medical acquisition

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Listen: Explaining the E.U.’s pharma overhaul, Lilly’s booming business, & a long-awaited drug approval

Listen: Explaining the E.U.’s pharma overhaul, Lilly’s ...

Apr 27, 2023

FDA lifts two-year clinical hold on CytoDyn’s HIV trial

FDA lifts two-year clinical hold on CytoDyn’s HIV trial

Mar 1, 2024

AstraZeneca files patent for improved production of aav...

Mar 13, 2024